BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 19389564)

  • 1. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?".
    Balligand JL
    J Am Coll Cardiol; 2009 Apr; 53(17):1539-42. PubMed ID: 19389565
    [No Abstract]   [Full Text] [Related]  

  • 5. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: negative inotropy and NO-cGMP-dependent mechanism.
    Imbrogno S; Angelone T; Adamo C; Pulerà E; Tota B; Cerra MC
    J Exp Biol; 2006 Dec; 209(Pt 24):4966-73. PubMed ID: 17142685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neither K+ channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries.
    Wang Y; Zhang M; Liu Y; Li J; Song E; Niu L; Cheng N
    J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):332-8. PubMed ID: 19903983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
    Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization.
    Dessy C; Moniotte S; Ghisdal P; Havaux X; Noirhomme P; Balligand JL
    Circulation; 2004 Aug; 110(8):948-54. PubMed ID: 15302798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENOS is not activated by nebivolol in human failing myocardium.
    Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
    Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium.
    Napp A; Brixius K; Pott C; Ziskoven C; Boelck B; Mehlhorn U; Schwinger RH; Bloch W
    J Card Fail; 2009 Feb; 15(1):57-67. PubMed ID: 19181295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S; Kozlovski VI; Gryglewski RJ
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.
    Rozec B; Quang TT; Noireaud J; Gauthier C
    Br J Pharmacol; 2006 Apr; 147(7):699-706. PubMed ID: 16474420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.
    Gauthier C; Leblais V; Kobzik L; Trochu JN; Khandoudi N; Bril A; Balligand JL; Le Marec H
    J Clin Invest; 1998 Oct; 102(7):1377-84. PubMed ID: 9769330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.